A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Explore this paper's citation graph
Summary
The study shows lower in-stent late loss at 9 months with the EES XIENCE V compared with the PES TAXUS Libertè, and a low major adverse cardiac event rate at 1 year in patients with 2- to 3-vessel MV-CAD.
- Type
- article
- Published
- 2013-10-01
- Cited by
- 31
- References
- 37
- Access
- Open access
- OpenAlex
- https://openalex.org/W29034173
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205795194
Keywords
Medicine, Clinical endpoint, Coronary artery disease, Stent, Myocardial infarction
References
- Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions.
- A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years.
- The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.
- Strategies for multivessel revascularization in patients with diabetes.
- Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De
- A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
- Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II.
- Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
- Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
- The effect of completeness of revascularization on event-free survival at one year in the ARTS trial.
- Guidelines on myocardial revascularization.
- A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
- Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.
- Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
- Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
- Long-Term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Multivessel Coronary Artery Disease: A Meta-Analysis With 5-Year Patient-Level Data From the ARTS, ERACI-II, MASS-II, and SoS Trials
- Thomas B. Ferguson Lecture. Coronary artery bypass grafting is still the best treatment for multivessel and left main disease, but patients need to know.
- Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.
- Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators.
- 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions.
Cited by
- Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study Design and Rationale
- A Tale of Two Techniques: Demystifying the Myth
- Complex coronary artery disease: would outcomes from the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) trial have differed with newer-generation drug-eluting stents?
- Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis
- Stenting and Adjunctive Delivery of Paclitaxel Via Balloon Coating Versus Durable Polymeric Matrix for De Novo Coronary Lesions: Clinical and Angiographic Results from the Prospective Randomized Trial.
- Paclitaxel-eluting stents in ST-segment elevation myocardial infarction.
- Long-term risk of late and very late stent thrombosis in patients treated with everolimus against paclitaxel-eluting stents: an updated meta-analysis
- Stents liberadores de paclitaxel en el infarto agudo de miocardio con elevación del segmento ST
- Drug-eluting stent or coronary artery bypass graft surgery in hemodialysis patients?
- First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients
- Stainless steel/nitinol braid coronary stents: Braiding structure stability and cut section treatment evaluation
- Impact of catheter size on reliability of quantitative coronary angiographic measurements (comparison of 4Fr and 6Fr catheters)
- Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease.
- Comparison of clinical outcomes after multivessel versus single-vessel stenting with the zotarolimus-eluting stent in the RESOLUTE Global Clinical Trial Program.
- A clinical evaluation of the XIENCE V everolimus eluting stent in the treatment of patients with coronary artery disease: Result from Thailand Registry – XIENCE V performance evaluation (THRIVE study)
- Long-term comparative effectiveness of paclitaxel-eluting and everolimus-eluting stents in New York.
- Predictors of Procedural Success Among Filipino Patients who Underwent Multi-Vessel Percutaneous Coronary Intervention
- Meta-Analysis of Randomized Control Trials Comparing Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Significant Left Main Coronary Narrowing.
- Risk and timing of clinical events according to diabetic status of patients treated with everolimus‐eluting bioresorbable vascular scaffolds versus everolimus‐eluting stent: 2‐year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials
- Clinical Outcomes after Triple Vessel Angioplasty in Diabetic Patients with Triple Vessel Coronary Artery Disease
Related papers
- Influence of revascularization by percutaneous coronary intervention on the life quality of elderly patients with multivessel coronary artery disease
- AS-144: Impact of Age on the Percutaneous Coronary Intervention Outcomes in the Drug-Eluting Stent Era
- Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, multicentre e-Ultimaster registry.
- [Present circumstance around percutaneous coronary intervention (PCI): before and after drug eluting stent (DES) introduction].
- mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response
- One year clinical outcomes in patients with chronic kidney disease treated by percutaneous coronary intervention with drug-eluting stent.
- TCT-31 Clinical Impact of Genetics on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention Using Drug-Eluting Stent
- Long term outcomes in octogenarians undergoing percutaneous coronary intervention: comparison of bare metal versus drug eluting stent.
- AS-189: Incidence and Clinical Outcomes Associated with Stent Fracture in Contemporary Percutaneous Coronary Intervention with Drug-Eluting Stents